NCT07323134Not yet recruiting
The Effect of Semaglutide on the Intestinal Flora in Obesity
Source: ClinicalTrials.gov · Last updated 7 Jan 2026
Brief summary (registry, in English)
For obese individuals, semaglutide treatment was adopted. By using multi-omics techniques such as fecal metagenomic sequencing and based on in vitro strain screening platforms, the effects and specific mechanisms of semaglutide on the intestinal flora of obese patients were clarified.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 13 Jul 2025
- Start date
- 1 Feb 2026
- Primary completion date
- 1 Aug 2026
- Lead sponsor
- Beijing Chao Yang Hospital
- Diseases
- Obesity
- NCT number
- NCT07323134
What you commit to
- Study type: Observational
- Planned participants: 40
- From 1 Feb 2026 to the primary completion date, 1 Aug 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Weight changes within 3 months prior to screening (self-reported) \>5%;
- Having received any drug treatment for obesity within the three months prior to screening;
- Participants who have received treatment with immunosuppressants, steroids, antidiarrheal drugs, antibiotics, probiotics, lipid-lowering drugs and/or other gastrointestinal motility drugs within 3 months prior to screening;
- Previously diagnosed overweight or obesity due to endocrine causes, such as Cushing's syndrome, etc;
Other illness
- It is known that there are clinically significant gastric emptying abnormalities (e.g., severe diabetic gastroparesis or gastric outlet obstruction), a history of gastrointestinal diseases and surgical history;
- History of mental illness;
- History of multiple endocrine tumors or medullary thyroid cancer, family history, or calcitonin ≥6pg/mL;
- History of cardiovascular diseases;
- History of malignant tumors;
- As determined by the researcher, there are other physical, psychological or other conditions that make one unsuitable to participate in the trial.
Lab values
- The application of hypoglycemic drugs within 3 months before screening, or HbA1c≥ 6.5%, or a history of type 1 or type 2 diabetes;
- Abnormal liver function during screening, that is, alanine aminotransferase and/or aspartate aminotransferase \> 3\*ULN;
Other
- Triglycerides ≥500mg/dL (5.65mmol/L) during screening;
- Abnormal thyroid function;
- Abnormal renal function during screening, that is, the estimated glomerular filtration rate is less than 60mL/min/1.75m2;
- Pregnancy or lactation;
Who the study is looking for
- 18 to 60 years old;
- BMI ≥ 30kg/m²;
- At least one self-reported history of unsuccessful lifestyle weight loss;
- Subjects who agree to participate in the project and sign the informed consent form.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.